# OnCo record bolero-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/bolero-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "bolero-2", "NCT00863655" ;
  schema:name "BOLERO-2"@en ;
  schema:description "BOLERO-2 showed that adding the mTOR inhibitor everolimus to the hormone drug exemestane more than doubled the time that advanced breast cancer stayed under control after aromatase inhibitors had stopped working, the first targeted drug to overcome endocrine resistance."@en ;
  schema:url <https://onco.cc/trials/bolero-2/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00863655> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/>, <https://onco.cc/cancers/breast-cancer/> ;
  onco:drugs <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/exemestane/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:people <https://onco.cc/people/jose-baselga/> .